Halozyme Therapeutics | HALO - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.72B 134M 2026-06
Baxter International USD 735M 7M 2026-06
Cara Therapeutics USD 2.09M 96K 2026-03
Cytokinetics USD 104.4M 499K 2026-06
DBV Technologies USD 13.4M 8.14M 2026-03
Eli Lilly USD 3.43B 496M 2026-06
Halozyme Therapeutics USD 57M 10.71M 2026-06
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
MannKind USD 58.3M 4.22M 2026-06
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Pfizer USD 3.41B 496M 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
United Therapeutics USD 206.7M 50.1M 2026-06
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12